drugset / Trial / NCT03479892

A Research Study Looking at a New Study Medicine (NNC0194-0499) for Weight Control in People With Overweight or Obesity

NCT03479892

Phase 1 Completed 57 enrolled Novo Nordisk A/S
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study looks at a new study medicine for weight control in people with overweight or obesity. The aim of this study is to see if the study medicine is safe for people to take. The study also looks at how fast the body removes the study medicine. The participants will either get NNC0194-0499 (the study medicine) or placebo (a formula that looks like the medicine but does not have active ingredients). Which treatment the participants get is decided by chance. The participants will get 1 or more injections into the skin of stomach area once each week for 12 weeks. The study will last for about 4 to 5 months. The participants will have 18 visits to the clinic.

Timeline

Start
2018-03-13
Primary completion
2019-06-04
Completion
2019-06-04

Drugs

EvaluationDrugModalityDoseRoute
Subject zalfermin Protein / enzyme biologic 3 mg Subcutaneous
Subject zalfermin Protein / enzyme biologic 9 mg Subcutaneous
Subject zalfermin Protein / enzyme biologic 27 mg Subcutaneous
Subject zalfermin Protein / enzyme biologic 60 mg Subcutaneous
Subject zalfermin Protein / enzyme biologic 120 mg Subcutaneous